Tirzepatide vs Retatrutide 2026: Dual vs Triple Agonist Compared
Tirzepatide (approved, available) vs retatrutide (Phase 3, not yet approved): head-to-head comparison of mechanisms, clinical trial weight loss results, side effects, availability timeline, and cost projections for 2026.
More on Comparisons
Eli Lilly created the GLP-1 drug class's current gold standard with tirzepatide — a dual GIP/GLP-1 agonist that outperforms semaglutide by a meaningful margin. Now the same company is pushing further with retatrutide, a triple agonist that adds glucagon receptor activation to the mix. Phase 2 results suggest even greater weight loss. But retatrutide is years away from patients.
This guide cuts through the hype to give you a clear, honest comparison: what each drug does mechanistically, what the clinical evidence actually shows, what we don't yet know about retatrutide, and the practical answer to the question most patients ask — should I start tirzepatide now, or wait for something potentially better?
Key fact for 2026: Tirzepatide is FDA-approved and available. Retatrutide is in Phase 3 trials with no approval expected until 2027–2028 at the earliest. The comparison below reflects clinical trial data, not real-world equivalence.
Quick Comparison: Tirzepatide vs Retatrutide
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual GLP-1 + GIP agonist | Triple GLP-1 + GIP + Glucagon agonist |
| Developer | Eli Lilly | Eli Lilly |
| FDA Status | Approved (Mounjaro / Zepbound) | Phase 3 (TRIUMPH trials) |
| Available Now? | Yes | No |
| Avg. Weight Loss (trial) | 22.5% at 72 weeks (SURMOUNT-1) | 24.2% at 48 weeks (Phase 2, highest dose) |
| Dosing | Weekly injection (2.5–15mg) | Weekly injection (1–12mg, Phase 3 dose TBD) |
| Compounded cost (Trimi) | From $125/month | Not available |
| Realistic availability | Today | 2027–2028 at earliest |
The Science: Dual Agonist vs Triple Agonist
To understand what separates tirzepatide from retatrutide, you need to understand the three hormone receptors at play and what each one does in the context of weight regulation.
GLP-1 Receptor Agonism (Both Drugs)
GLP-1 (glucagon-like peptide-1) is an incretin hormone produced in the gut after meals. Activating the GLP-1 receptor delivers multiple weight-relevant effects:
- Appetite suppression: Acts on hypothalamic feeding centers to reduce hunger and food cravings
- Gastric emptying delay: Slows food movement from stomach to small intestine, prolonging satiety
- Insulin secretion: Stimulates glucose-dependent insulin release, improving blood sugar control
- Glucagon suppression: Reduces post-meal glucagon release to prevent blood sugar spikes
GLP-1 agonism is the foundation of the entire weight loss drug class. It explains why semaglutide, tirzepatide, and retatrutide all work — but it doesn't explain why tirzepatide and retatrutide are more effective than semaglutide alone. That comes from the additional receptors. For a detailed breakdown of how GLP-1 works in the body, see our complete guide to how GLP-1 medications work.
GIP Receptor Agonism (Both Drugs)
GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. Its addition is what makes tirzepatide a "dual agonist" and separates it from semaglutide. GIP receptor agonism contributes to tirzepatide's weight loss advantage through several pathways:
- Enhanced insulin sensitivity: GIP improves how efficiently cells respond to insulin, reducing fat storage signals
- Fat tissue signaling: GIP receptors are present in adipose tissue and may directly influence fat cell metabolism
- Synergistic appetite suppression: Combined with GLP-1, GIP activation produces greater appetite reduction than either alone — this synergy is the key reason tirzepatide outperforms semaglutide
- GI tolerability: Counterintuitively, GIP co-agonism may slightly buffer GLP-1's GI side effects, helping tirzepatide's tolerability profile
Glucagon Receptor Agonism (Retatrutide Only)
This is where retatrutide diverges from tirzepatide — and where the drug's potentially greater efficacy comes from. Glucagon is typically known as the "raise blood sugar" hormone, which makes activating its receptor seem like the wrong direction for a metabolic drug. The mechanism is more nuanced in practice:
- Thermogenesis activation: Glucagon receptor agonism stimulates brown adipose tissue to generate heat, increasing total daily energy expenditure beyond what GLP-1 and GIP achieve alone
- Hepatic fat oxidation: Glucagon drives the liver to burn stored fat for energy, contributing to both weight loss and fatty liver improvement
- Resting metabolic rate increase: By elevating the body's baseline calorie burning, glucagon agonism helps close the "metabolic adaptation" gap — the reduction in energy expenditure that typically counteracts caloric restriction
The blood sugar risk from glucagon activation is offset by the robust insulin-stimulating effects of GLP-1 and GIP at the same time. In clinical trials, retatrutide has not produced problematic hyperglycemia, validating the theoretical safety of this combined approach. For an in-depth look at how glucagon fits into retatrutide's design, see our article on retatrutide's glucagon receptor mechanism.
Mechanism Summary
Tirzepatide suppresses appetite and improves insulin sensitivity through two hormone pathways. Retatrutide does all of that — plus adds a third pathway that increases the body's energy expenditure. The extra glucagon agonism is effectively adding a metabolic accelerator to the appetite brake that tirzepatide already provides.
Clinical Trial Results: The Numbers
Tirzepatide: SURMOUNT Trial Program
Tirzepatide's efficacy in obesity is established through the SURMOUNT clinical trial program, with SURMOUNT-1 as the landmark Phase 3 study:
SURMOUNT-1 Results (72 weeks, adults without diabetes)
56.7% of participants on tirzepatide 15mg achieved ≥20% weight loss — a threshold previously associated only with bariatric surgery.
Beyond SURMOUNT-1, tirzepatide has been studied in patients with type 2 diabetes (SURMOUNT-2), heart failure with preserved ejection fraction (SURMOUNT-HFpEF), and sleep apnea. These trials add to an unusually comprehensive body of evidence for an obesity medication. For the full trial breakdown, visit our deep-dive on GLP-1 trial results.
Retatrutide: TRIUMPH Phase 2 Data
Retatrutide's Phase 2 trial, published in the New England Journal of Medicine in 2023, generated significant excitement in the obesity medicine community:
TRIUMPH Phase 2 Results (48 weeks, adults without diabetes)
At the 12mg dose, the weight loss curve had not plateaued by week 48, suggesting higher total loss was still occurring at trial end — a sign Phase 3 numbers over a full 72 weeks could be higher.
The headline 24.2% figure is genuinely impressive. However, Phase 2 trials have important limitations: smaller sample sizes, often younger and healthier patients, and less rigorous real-world population representation. Phase 3 TRIUMPH trials are the definitive test. To track Phase 3 updates as they emerge, see our retatrutide TRIUMPH trial updates page.
Important: Comparing Phase 2 vs Phase 3 data
Tirzepatide's 22.5% comes from large, definitive Phase 3 trials. Retatrutide's 24.2% comes from a smaller Phase 2 study. Phase 2 results historically overestimate final outcomes by 2–4 percentage points on average. The real gap between these two drugs in large Phase 3 trials may be smaller than current numbers suggest.
Side Effects: What to Expect from Each Drug
Both tirzepatide and retatrutide are GLP-1 receptor agonists at their core, so they share a fundamental side effect profile driven by that mechanism.
Tirzepatide Side Effects
- Nausea (18–35% during escalation)
- Diarrhea (12–23%)
- Vomiting (8–13%)
- Constipation (7–15%)
- Injection site reactions (mild)
- Modest heart rate increase (~2–3 bpm)
- Rare: pancreatitis, gallbladder disease
GI effects peak during dose escalation and typically improve. Full safety data from 5+ years of real-world use.
Retatrutide Side Effects (Phase 2 data)
- Nausea (slightly higher rate than tirzepatide)
- Vomiting, diarrhea, constipation (similar profile)
- Heart rate increase (more pronounced; ~4–5 bpm average)
- Injection site reactions (mild)
- Potential dysesthesia (abnormal sensation) in some patients
- Full safety profile still being characterized in Phase 3
The heart rate elevation linked to glucagon agonism is a specific concern being monitored carefully in Phase 3.
The most clinically notable difference in the side effect profiles is heart rate elevation. Both drugs increase resting heart rate slightly — a class effect seen across GLP-1 medications — but retatrutide's glucagon component adds additional sympathomimetic stimulation. In Phase 2, the average heart rate increase was modestly higher for retatrutide than tirzepatide. Whether this translates to any clinical concern will be answered by Phase 3 cardiovascular data.
For patients with pre-existing cardiac conditions, this is an important consideration and one that a prescribing clinician would evaluate. For most otherwise healthy adults with obesity, the small heart rate increase seen with tirzepatide has not translated to adverse outcomes. For information on managing tirzepatide side effects, see our guide to GLP-1 side effects and management.
Availability Timeline: When Can You Get Each Drug?
Tirzepatide: Available Now
Tirzepatide is FDA-approved under two brand names:
- Mounjaro: Approved for type 2 diabetes management (2022)
- Zepbound: Approved for chronic weight management in adults with obesity or overweight with a weight-related condition (2023)
Compounded tirzepatide is also available through licensed telehealth providers while supply conditions allow. Trimi offers compounded tirzepatide starting at $125/month — the most affordable entry point currently available with physician oversight and ongoing support.
Retatrutide: 2027–2028 at Earliest
Retatrutide's path to approval involves completing Phase 3 TRIUMPH trials, FDA submission, regulatory review, and manufacturing scale-up. Each step takes time:
Estimated Retatrutide Timeline
Timeline assumes no major safety signals emerge in Phase 3 and trials complete on schedule. Delays at any stage would push the timeline back.
For the latest updates on where retatrutide stands in its regulatory journey, see our retatrutide FDA timeline tracker and our retatrutide availability tracker.
Cost Projections: What Will Retatrutide Cost?
No official pricing exists for retatrutide — it's years from market. However, we can project based on the current pricing landscape:
| Drug | Brand-name cost | Compounded cost | Available |
|---|---|---|---|
| Tirzepatide (Zepbound) | $1,000–$1,300/month | From $125/month (Trimi) | Now |
| Semaglutide (Wegovy) | $900–$1,100/month | From $199/month | Now |
| Retatrutide (projected) | ~$1,100–$1,500/month (est.) | TBD / unlikely at launch | 2027–2028 |
Retatrutide will likely launch at a premium price point given its greater efficacy. Eli Lilly has demonstrated with Zepbound that they will price new weight loss drugs aggressively. Unless a shortage similar to 2023–2024 occurs, compounded retatrutide would not be legally available at launch — compounding is only FDA-permitted when a drug is on the shortage list.
For a comprehensive look at how to access GLP-1 medications affordably today, see our guide to affordable GLP-1 injections.
What's Available Now: Tirzepatide from $125/Month at Trimi
Retatrutide is compelling science, but it isn't available to patients today and won't be for at least two to three years. Tirzepatide produces clinically transformative weight loss — up to 22.5% of body weight — and is available right now.
Trimi makes tirzepatide accessible with:
- Compounded tirzepatide starting at $125/month — a fraction of Zepbound's $1,000+ brand price
- Licensed physician oversight and ongoing medical support
- Fast online intake — no in-person visit required
- Pharmacy-grade compounded medication shipped to your door
Subject to physician approval. Results vary. Compounded tirzepatide is not FDA-approved as a finished drug product. See treatments page for full details.
Should You Wait for Retatrutide?
This is the practical question behind every "tirzepatide vs retatrutide" search. The answer requires weighing several factors:
Reasons to start tirzepatide now
- You get real weight loss benefits starting today, not in 2027–2028
- Every month of treatment is compounding metabolic improvement — reduced blood pressure, improved blood sugar, less joint stress
- Tirzepatide produces 20%+ weight loss for many patients — this is genuinely excellent by any historical standard
- If retatrutide is approved and proves clearly superior, you can switch at that time
- Tirzepatide's long-term safety profile is better characterized than retatrutide's will be at initial approval
- Cost: tirzepatide compounded is available for $125/month; retatrutide at launch will be brand-name only at $1,100+
Reasons you might consider waiting
- You've already tried tirzepatide and achieved inadequate results — retatrutide's additional mechanism might help
- You have specific risk factors that make tirzepatide suboptimal and your provider agrees waiting makes clinical sense
- You have no urgent metabolic health concerns and are willing to invest in monitoring lifestyle factors for 2–3 years
For the vast majority of patients, the evidence strongly favors starting an effective, available medication now. Obesity is a progressive metabolic disease — each year without treatment is a year of ongoing cardiovascular, metabolic, and joint burden. To understand who the ideal candidate for retatrutide might be once it's available, see our article on who should wait for retatrutide.
Frequently Asked Questions
What is the difference between tirzepatide and retatrutide?
Tirzepatide is a dual GLP-1/GIP receptor agonist that is FDA-approved and available now (as Mounjaro for type 2 diabetes and Zepbound for obesity). Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist developed by Eli Lilly that is still in Phase 3 clinical trials and has not been approved by the FDA. The addition of glucagon receptor agonism is the key pharmacological difference — it boosts energy expenditure on top of appetite suppression, which may explain retatrutide's higher Phase 2 weight loss numbers.
Does retatrutide produce more weight loss than tirzepatide?
Based on Phase 2 data, retatrutide showed up to 24.2% average body weight loss at 48 weeks at the highest dose (12mg), compared to tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. However, these are from different trials with different patient populations and durations, so direct comparison has limitations. Phase 3 TRIUMPH trial data will provide more definitive numbers. Importantly, tirzepatide is available today while retatrutide is not.
When will retatrutide be FDA approved?
Retatrutide is currently in Phase 3 TRIUMPH clinical trials. Based on current trial timelines and typical regulatory review periods, the earliest realistic FDA approval would be late 2027 to 2028. There is no guarantee of approval — Phase 3 results must confirm Phase 2 efficacy and the full safety profile must be acceptable to regulators. Any approved drug will then take additional months to reach pharmacy shelves at scale.
What does glucagon receptor agonism add to retatrutide?
Glucagon is typically associated with raising blood sugar, which is why activating the glucagon receptor might seem counterintuitive for a metabolic drug. However, in the context of obesity treatment, glucagon receptor agonism stimulates thermogenesis (heat production) in brown adipose tissue, increases the liver's fat-burning activity, and raises resting energy expenditure. The net effect when combined with GLP-1 and GIP is greater fat loss without corresponding muscle loss — a potentially important advantage over dual agonists.
Is retatrutide safe?
Based on Phase 2 data, retatrutide's side effect profile is consistent with the GLP-1 drug class: nausea, vomiting, diarrhea, and constipation are the most common adverse events, predominantly occurring during dose escalation. The rate of GI side effects in Phase 2 was similar to or slightly higher than tirzepatide. Heart rate elevations were observed, an effect also seen with other GLP-1 drugs. Full safety characterization from the large Phase 3 TRIUMPH trials is required before regulatory approval.
How much will retatrutide cost?
No official pricing has been announced since retatrutide is not yet approved. Analysts project brand-name pricing will be comparable to or higher than current GLP-1 medications ($1,000–$1,400/month) based on the drug's greater efficacy and Eli Lilly's pricing strategy for tirzepatide. Compounded versions would not be available unless a shortage occurs similar to tirzepatide and semaglutide shortages in 2023–2024. Insurance coverage will depend on final indication approvals and formulary decisions.
Should I wait for retatrutide instead of starting tirzepatide?
For most patients, waiting is not advisable. Tirzepatide produces clinically significant weight loss (20–22%) that is already available and proven. Every month of delay means another month without treatment, continued health risks from obesity, and foregone metabolic benefits. If retatrutide is eventually approved and shows meaningfully superior outcomes, switching at that time is straightforward. Starting tirzepatide now through a provider like Trimi (starting at $125/month) allows you to begin your health journey without a 2–3 year wait.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Retatrutide is an investigational drug not yet approved by the FDA; clinical trial results may not predict final outcomes or real-world performance. Tirzepatide is FDA-approved but carries risks and contraindications including a boxed warning regarding thyroid C-cell tumors. Always consult a licensed healthcare provider before starting, changing, or stopping any prescription medication. Individual results vary.
Sources & References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." NEJM. 2022;387(3):205-216. (SURMOUNT-1)
- Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM. 2023;389(6):514-526.
- Eli Lilly and Company. TRIUMPH Phase 3 Clinical Trial Program. ClinicalTrials.gov identifiers: NCT05929079 and related trials.
- FDA Prescribing Information: Zepbound (tirzepatide) injection. 2023.
- Nahra R, et al. "Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes." Cell Metabolism. 2021.
- Frias JP, et al. "Efficacy and Safety of LY3437943, a Novel Triple GIP, GLP-1 and Glucagon Receptor Agonist in Patients with Type 2 Diabetes." Lancet. 2021;398(10295):143-155.
- Drucker DJ. "GLP-1 physiology informs the pharmacotherapy of obesity." Molecular Metabolism. 2022;57:101351.